Validea Detailed Fundamental Analysis

Validea's analysis indicates Johnson & Johnson (JNJ), a large-cap growth stock in Biotechnology & Drugs, scored an 88% rating using its Partha Mohanram P/B Growth Investor model. This model, known for identifying sustained future growth potential in low book-to-market stocks and challenging conventional academic views on growth investing, found JNJ passed most financial criteria, including return on assets and cash flow, but notably failed the Research & Development to Assets test. The 88% score suggests significant interest in JNJ based on its underlying fundamentals and valuation according to this strategy.

Analysis

Johnson & Johnson (JNJ) has been identified as a high-potential, large-cap growth stock, scoring 88% on Validea's P/B Growth Investor model, which is based on the academic work of Partha Mohanram. A score above 80% indicates significant interest from this specific strategy, which focuses on identifying low book-to-market stocks with characteristics of sustained future growth. JNJ's strong performance is supported by its passing of eight fundamental tests, including key indicators like Return on Assets (ROA), Cash Flow From Operations to Assets, and stability measures such as ROA and Sales Variance. However, the analysis reveals a notable weakness, as the company failed the test for Research and Development to Assets. This specific failure introduces a point of caution, suggesting that while the company's current financial health and operational efficiency are strong, its investment in future innovation relative to its asset base may not meet the model's criteria for a top-tier growth stock.

Key Decisions for Investors

• Investors with a growth-focused strategy should consider the 88% score a strong quantitative signal, backed by JNJ's robust performance on profitability and cash flow metrics.
• The failure on the Research and Development to Assets metric warrants further investigation, as it may signal a potential underinvestment in the company's long-term innovation pipeline, a critical factor in the Biotechnology & Drugs industry.
• This analysis is based on a specific academic model and should be used as one component of a broader due diligence process, not as a standalone investment thesis.